Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-29
2011-03-29
Romeo, David S (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018700, C514S169000, C514S863000, C552S588000, C607S094000, C530S350000, C530S866000
Reexamination Certificate
active
07915225
ABSTRACT:
The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNFα by administering a TNFα antagonist, such as recombinant TNFR:Fc.
REFERENCES:
patent: 4006224 (1977-02-01), Prudden
patent: 4965271 (1990-10-01), Mandrell et al.
patent: 5096906 (1992-03-01), Mandrell et al.
patent: 5196430 (1993-03-01), Mandrell et al.
patent: 5342613 (1994-08-01), Creaven et al.
patent: 5344915 (1994-09-01), LeMaire et al.
patent: 5420154 (1995-05-01), Christensen et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5508300 (1996-04-01), Duplantier
patent: 5541219 (1996-07-01), Fenton et al.
patent: 5545614 (1996-08-01), Stamler et al.
patent: 5563143 (1996-10-01), Cohan et al.
patent: 5596013 (1997-01-01), Duplantier
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5610279 (1997-03-01), Brockhaus et al.
patent: 5629285 (1997-05-01), Black et al.
patent: 5641814 (1997-06-01), Martin
patent: 5656272 (1997-08-01), Le et al.
patent: 5658581 (1997-08-01), De Lacharriere et al.
patent: 5691382 (1997-11-01), Crimmin et al.
patent: 5698195 (1997-12-01), Le et al.
patent: 5700838 (1997-12-01), Dickens et al.
patent: 5714146 (1998-02-01), Lewis et al.
patent: 5747514 (1998-05-01), Beckett et al.
patent: 5756449 (1998-05-01), Andersen et al.
patent: 5767065 (1998-06-01), Mosley et al.
patent: 5795859 (1998-08-01), Rathjen et al.
patent: 5821262 (1998-10-01), Crimmin et al.
patent: 5834485 (1998-11-01), Dyke et al.
patent: 5869511 (1999-02-01), Cohan et al.
patent: 5872146 (1999-02-01), Baxter et al.
patent: 5888511 (1999-03-01), Skurkovich et al.
patent: 5902827 (1999-05-01), Pamukcu et al.
patent: 5919452 (1999-07-01), Le et al.
patent: 5958413 (1999-09-01), Anagnostopulos et al.
patent: 5993833 (1999-11-01), De Lacharriere et al.
patent: 5994510 (1999-11-01), Adair et al.
patent: 6015557 (2000-01-01), Tobinick et al.
patent: 6020323 (2000-02-01), Cohen et al.
patent: 6083534 (2000-07-01), Wallach et al.
patent: 6107349 (2000-08-01), Mantynen
patent: 6117895 (2000-09-01), Wachtel et al.
patent: 6143730 (2000-11-01), Parish et al.
patent: 6143866 (2000-11-01), Brewer et al.
patent: 6177077 (2001-01-01), Tobinick
patent: 6221675 (2001-04-01), Hauptmann et al.
patent: 6277387 (2001-08-01), De Lacharriere et al.
patent: 6277969 (2001-08-01), Le et al.
patent: 6284471 (2001-09-01), Le et al.
patent: 6300349 (2001-10-01), Margolin
patent: 6306820 (2001-10-01), Bendele et al.
patent: 6313269 (2001-11-01), Deen et al.
patent: 6379666 (2002-04-01), Tobinick
patent: 6419934 (2002-07-01), Tobinick
patent: 6495604 (2002-12-01), Ichimori et al.
patent: 6498237 (2002-12-01), Rathjen et al.
patent: 6537540 (2003-03-01), Burstein et al.
patent: 6537549 (2003-03-01), Tobinick
patent: 6572852 (2003-06-01), Smith
patent: 6673908 (2004-01-01), Stanton, Jr.
patent: 6989147 (2006-01-01), Fisher et al.
patent: 7122183 (2006-10-01), Mohler et al.
patent: 7253264 (2007-08-01), Lauffer et al.
patent: 7335358 (2008-02-01), Le et al.
patent: 2002/0012962 (2002-01-01), Stahl et al.
patent: 2002/0022720 (2002-02-01), Le et al.
patent: 2002/0183485 (2002-12-01), Hauptmann et al.
patent: 2003/0012786 (2003-01-01), Teoh et al.
patent: 2003/0054439 (2003-03-01), Fisher et al.
patent: 2003/0086925 (2003-05-01), Skurkovich et al.
patent: 2003/0103942 (2003-06-01), Burstein et al.
patent: 2003/0113318 (2003-06-01), Tobinick
patent: 2003/0143603 (2003-07-01), Giles-Komar et al.
patent: 0 308 378 (1989-03-01), None
patent: 0 325 471 (1989-07-01), None
patent: 0 393 438 (1990-10-01), None
patent: 0 398 327 (1990-11-01), None
patent: 0 422 339 (1991-04-01), None
patent: 0 516 785 (1992-12-01), None
patent: 0 567 566 (1993-11-01), None
patent: 0 639 079 (1993-11-01), None
patent: 0 377 823 (1994-07-01), None
patent: 0 626 389 (1994-11-01), None
patent: GB 2291422 (1996-01-01), None
patent: 0 839 046 (1998-05-01), None
patent: 0 869 179 (1998-10-01), None
patent: 0 870 827 (1998-10-01), None
patent: 0 927 758 (1999-07-01), None
patent: 0 958 820 (1999-11-01), None
patent: 0 610 201 (2001-05-01), None
patent: 1 097 945 (2001-05-01), None
patent: 1 170 017 (2002-09-01), None
patent: WO 92/01472 (1992-02-01), None
patent: WO 92/13095 (1992-08-01), None
patent: WO 92/16221 (1992-10-01), None
patent: WO 92/16553 (1992-10-01), None
patent: WO 95/06031 (1995-03-01), None
patent: WO 95/20402 (1995-08-01), None
patent: WO 95/34326 (1995-12-01), None
patent: WO 95/35283 (1995-12-01), None
patent: WO 95/35285 (1995-12-01), None
patent: WO 96/00215 (1996-01-01), None
patent: WO 96/01825 (1996-01-01), None
patent: WO 96/04388 (1996-02-01), None
patent: WO 97/29131 (1997-08-01), None
patent: WO 97/41895 (1997-11-01), None
patent: WO 98/01555 (1998-01-01), None
patent: WO 98/05357 (1998-02-01), None
patent: WO 98/17799 (1998-04-01), None
patent: WO 98/24463 (1998-06-01), None
patent: WO 98/24463 (1998-08-01), None
patent: WO 98/46642 (1998-10-01), None
patent: WO 98/51344 (1998-11-01), None
patent: WO 98/54201 (1998-12-01), None
patent: WO 99/15524 (1999-04-01), None
patent: WO 99/18095 (1999-04-01), None
patent: WO 99/31128 (1999-06-01), None
patent: WO 99/31128 (1999-06-01), None
patent: WO 99/46242 (1999-09-01), None
patent: WO 00/67790 (2000-11-01), None
patent: WO 00/73481 (2000-12-01), None
patent: WO 01/00229 (2001-01-01), None
patent: WO 01/37874 (2001-05-01), None
Abu-Shakra, M., et al., “Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome,” J Rheumatol 22:241-245, 1995.
Alonso, J.C., et al., “Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients,” Br J Rheumatol 30:245-250, 1991.
Ameglio, F., et al., “Interleukin-6 and tumour necrosis factor levels decrease in the suction blister fluids of psoriatic patients during effective therapy,” Dermatology 189:359-363, 1994.
Antoni C. et al., “Successful treatment of severe psoriatic arthritis with infliximab,” Arthritis & Rheumatism, vol. 42, p. S371, Sep. 1999, Abstract 1801.
Arias, A, et al., “Tumor necrosis factor-alpha gene polymorphism in psoriasis,” Exp Clin Immunogenet 14:118-122, 1997.
Austin, L., et al., “Intracellular TNF-α, IFN-γ, and IL-2 identify TC1 and TH1 effector populations in psoriasis vulgaris plaque lymphocytes: single-cell analysis by flow cytometry,” J Dermatol Sci 16 (Suppl. 1), Mar. 1998.
Austin, L., et al., “Intracellular TNF-α, IFN-γ, and IL-2 identify TC1 and TH1 effector populations in psoriasis vulgaris plaque lymphocytes: single-cell analysis by flow cytometry,” J Invest Dermatol 1101 #4, Apr. 1998.
Barker, JNWN et al., “Marked synergism between tumor necrosis factor-α and interferon-γ in regulation of keratinocyte-derived adhesion molecules and chemotactic factors,” J Clin Invest 85:605-608, 1990.
Barnes et al., “Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases,” N Engl J Med 336(15):1066-1071, 1997.
Baum et al., “Treatment of psoriatic arthritis with 6-mercaptopurine,” Arthritis and Rheum., 16(2):139-147 (1973).
Bonifati, C., et al., “Correlated increases of tumour necrosis factor-α, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients—relationships with disease severity,” Clin Exp Dermatol 19:383-387, 1994.
Bonifati, C., et al., Soluble E-selectin and soluble tumour necrosis factor receptor (60kD) serum levels in patients with psoriasis, Dermatology 190:128-131, 1995.
Breathnach, S.M., “Spondyloarthropathies: psoriatic arthritis: etiology and pathogenesis,” inRheumatology, Mosby, London, John H. Klippel & Paul A. Dieppe, eds., 2d ed., 1998, pp. 22.1-22.4.
Brockbank and Gladman, “Diagnosis and management of psoriatric arthritis,” Drugs 62(17):2447-2457, 2002.
Bundow et al., “Etanercept: a treatmentoption for human immunodeficiency virus (HIV)-relate
Immunex Corporation
Romeo David S
Sweeney Rosemary
LandOfFree
Soluble tumor necrosis factor receptor treatment of medical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Soluble tumor necrosis factor receptor treatment of medical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble tumor necrosis factor receptor treatment of medical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2675275